Transforming Lives

Through a new class of safe, durable cancer treatments.

Our Team

Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.
Learn more
Our Science

Our approach uses a new class of compounds called imipridones to selectively target G protein-coupled receptors (GPCRs) that control critical signaling pathways in cancer.
Learn more
Alliances

Rutgers Cancer Institute of N.J., MD Anderson Cancer Center and Mass. General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.
Learn more

- JUN 09 2017
ONC201 Results in Glioblastoma Featured in Bioscience Technology
The recently published results from a clinical trial of ONC201 in patients with recurrent glioblastoma were featured in a recent article from Bioscience Technology. The full article can be read here.

Read >

- MAY 05 2017
GPCRs In The News: An Interview with Dr. Michel Bouvier
Cambridge Healthtech Institute recently spoke with Dr. Michel Bouvier of Université de Montréal about his insights on GPCRs and where the field is headed in coming years. The full interview can be found here.

Read >